<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04119947</url>
  </required_header>
  <id_info>
    <org_study_id>SY009001</org_study_id>
    <nct_id>NCT04119947</nct_id>
  </id_info>
  <brief_title>Single Ascending Oral Doses of SY-009 in Healthy Subjects</brief_title>
  <official_title>Evaluation of Safety, Tolerance and Pharmacokinetics/Pharmacodynamics of SY-009 Capsules After Single Dose Incremental Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ⅰ，single-center, randomized, double-blinded, placebo-controlled, single
      ascending dose trial of SY-009 in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dosed tolerability, pharmacokinetic /
      pharmacodynamic study of a single oral SY-009 capsule for Chinese healthy subjects. Plan to
      screening no more than 64 healthy subjects ， dividing them into 7 dose groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel ，Placebo control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Safety and tolerance of SY-009，Collecting Number of subjects with adverse events as assessed by CTCAE V5.0</measure>
    <time_frame>7 Days</time_frame>
    <description>Number of subjects with adverse events, major adverse events, serious adverse events, pregnancy events, abnormal Laboratory Values, abnormal vital signs, Abnormal physical examination, Abnormal ECG data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>area under curve (AUC) of SY-009 following oral administration of single ascending dose</measure>
    <time_frame>3 Days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of SY-009 following oral administration of single ascending dose</measure>
    <time_frame>3 Days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of SY-009 following oral administration of single ascending dose</measure>
    <time_frame>3 Days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (Clearance rectified) of SY-009 following oral administration of single ascending dose</measure>
    <time_frame>3 Days</time_frame>
    <description>to measure the study drug concentration in blood samples to be collected after drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose levels following single dose of SY-009</measure>
    <time_frame>3 Days</time_frame>
    <description>FPG AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin secretion following single dose of SY-009</measure>
    <time_frame>3 Days</time_frame>
    <description>insulin changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide secretion following single dose of SY-009</measure>
    <time_frame>3 Days</time_frame>
    <description>C-peptide change</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>SY-009 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-009 (0.5-40mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-009 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-009 (0.5-40mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-009 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-009 (0.5-40mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-009 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-009 (0.5-40mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-009 dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-009 (0.5-40mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-009 dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of SY-009 (0.5-40mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-009 matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>from 2-40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-009</intervention_name>
    <description>The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.</description>
    <arm_group_label>SY-009 dose 1</arm_group_label>
    <arm_group_label>SY-009 dose 2</arm_group_label>
    <arm_group_label>SY-009 dose 3</arm_group_label>
    <arm_group_label>SY-009 dose 4</arm_group_label>
    <arm_group_label>SY-009 dose 5</arm_group_label>
    <arm_group_label>SY-009 dose 6</arm_group_label>
    <arm_group_label>SY-009 matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1、healthy subject：determined by medical history, physical examination, Imaging examination,
        abdominal B-mode ultrasonography (include liver, gallbladder, pancreas, spleen and kidney),
        electrocardiogram and laboratory tests. Test results within the normal range for the
        population or investigator site, or with abnormalities deemed clinically insignificant by
        the investigator; 2、Gender: Male and female, gender balance; 3、Age: 18-65 years old
        (including the boundary values); 4、Weight ≥50kg and 19.0kg/m2≤BMI≤28.0kg/m2 [BMI=body
        weight（kg）/height 2 (m2); 5、fasting plasm glucose (FPG): 3.9-6.1mmol/L (excluding the
        boundary valuses); 6、2h postprandial plasma giucose（2hPPG）＜7.8mmol/L; 7、glycosylated
        hemoglobin (HbA1c) &lt;5.7%;

        8、have venous access sufficient to allow blood sampling as per the protocol;

        9、Subjects must have informed consent before the study and sign a written informed consent
        form voluntarily;

        10、Subjects can communicate well with investigator and complete the study according to the
        protocol.

        Exclusion Criteria:

          1. are investigator site personnel directly affiliated with this study and their
             immediate families. Immediate family is defined as a spouse, parent, child or sibling,
             whether biological or legally adopted.

          2. within 3 months prior to screening, complete or withdraw a clinical study, or are
             currently conducting a clinical study. Or are concurrently enrolled in any other type
             of medical research judged not to be scientifically or medically compatible with this
             study.

          3. have previously completed or withdrawn from this study.

          4. have known allergies to compounds related to SY-009 capsules or its adjuvants,or
             allergic constitution/allergic history, or SGLT1 or SGLT2 inhibitors taken in the past
             one year.

          5. with cardiovascular diseases, respiratory diseases, gastrointestinal diseases,
             endocrine diseases, blood system diseases, nervous system diseases, disease status can
             significantly change the absorption, distribution, metabolism and excretion of
             experimental drugs, or taking experimental drugs will increase the risk of subjects.

          6. In the past five years, there has been a history of drug abuse or drug abuse tests
             positive.

          7. show evidence or test positive on any of the following: hepatitis B virus surface
             antigen (HBsAg), hepatitis C virus antibody (HCV), Treponema pallidum antibody (S-TP),
             HIV (HIV1 + 2) antibody.

          8. Blood donation or massive blood loss exceeding 400 mL in the first three months prior
             to screening, or surgical operation and blood or blood component transfusion within
             the first four weeks prior to screening, or have history of fainting or needle
             fainting.

          9. Subjects who have an average weekly alcohol intake that exceeds and 14 units per week
             (1 unit = 360 mL beer, 45 mL alcohol content of 40% spirits or 150 mL wine) or
             subjects unwilling to stop alcohol consumption 24 hours prior to dosing until the
             completion of each inpatient study period.

         10. consume more than 5 cigarettes per day or the equivalent, or are unable or unwilling
             to refrain from nicotine during the study.

         11. intend to use any medicine or health care product within 14 days prior to dosing or
             during the study.

         12. subjects not agree to use reliable contraceptive methods (hormones or barriers or
             abstinence) during the study period and at least 1 month after administration.

         13. women were positive for blood pregnancy test within 24 hours prior to enrollment.

         14. pregnant or lactating women.

         15. Have special dietary requirements，and impossible to comply with the unified diet.

         16. Unable to stop eating chocolate, any caffeine-containing food or beverage (such as
             pitaya, grapefruit, orange juice, mango, etc.) 48 hours before administration and
             during the study.

         17. Within 30 days prior to screening, any drugs that inhibit or induce drug metabolic
             enzymes in the liver (e.g. barbiturates, carbamazepine, phenytoin sodium,
             glucocorticoids, omeprazole, SSRI antidepressants, cimetidine, diltiazem, macrolides,
             nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines) were
             used.

         18. in the opinion of the investigator , are unsuitable for inclusion in the study，or
             subjects withdraw informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingtong Li, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

